Hackensack Meridian Neuroscience Institute at JFK University Medical Center Receives $2.2 Million Research Grant to Study A Novel Traumatic Brain Injury Treatment

Summation

  • The Muneer lab at the Hackensack Meridian Neuroscience Institute at JFK University Medical Center seeks to demonstrate a unique therapeutic strategy for TBI focusing on the activation of leukocytes, especially neutrophils that cause the release of nuclear and granular contents to form an extensive web-like structure of DNA called neutrophil extracellular traps (NET).
  • “My research team and I will study an approach to suppressing the formation of NET, which may be a valuable therapeutic strategy, and analyze the efficacy of the therapy in the functional recovery level after TBI,” said Dr.
  • , FACS, president of Academics, Research, and Innovation at Hackensack Meridian Health, founding chair of the Hackensack Meridian Health Research Institute, and associate dean of Clinical Integration and professor and chair emeritus of Urology at the Hackensack Meridian School of Medicine.

Hackensack Meridian Neuroscience Institute at JFK University Medical Center

Hackensack Meridian Neuroscience Institute at JFK University Medical Center announced today that it has been awarded a major research grant from the National Institute of Neurological Disorders and Stroke, part of the U.S. National Institutes of Health, to study a novel approach on whether the blocking of formation of Neutrophil extracellular traps (NET) provides better outcomes after a Traumatic Brain Injury (TBI). The five-year award of $2,213,750 is part of the highly competitive NIH extramural grant application process that recognizes innovative scientific projects. NIH-funded research has led to scientific breakthroughs and new treatments that help people live longer, healthier lives.

Neutrophil Extracellular Traps And Associated Pathogenesis In TBI: A Novel Peptide Therapeutic Strategy

The NIH grant will fund a project entitled “Neutrophil Extracellular Traps And Associated Pathogenesis In TBI: A Novel Peptide Therapeutic Strategy” proposed by Mohammed Abdul Muneer, MSc, PhD, Research Scientist & Principal Investigator, Hackensack Meridian Neuroscience Institute at JFK University Medical Center, and Associate Professor of Neurology at the Hackensack Meridian School of Medicine.

The work hypothesizes that inhibition of peptidyl arginine deiminase type 4 (PAD4), an enzyme required for NET formation, using PAD4 antagonistic peptide (PAP), will attenuate the formation of NET, NET-induced thrombosis, and will promote neovascularization and functional recovery after TBI.

Gregory J. Przybylski, M.D.

“We are honored to receive this prestigious NIH grant,” said Gregory J. Przybylski, M.D., MBA, chairman, Hackensack Meridian Neuroscience Institute at JFK University Medical Center, and Professor of Neurosurgery at the Hackensack Meridian School of Medicine. “I congratulate Dr. Muneer and his team for this incredible achievement. This is yet another research grant that he has received from the NIH. It is a testament to his hard work, dedication, and leadership in the neuroscience field.”

The Muneer lab at the Hackensack Meridian Neuroscience Institute at JFK University Medical Center seeks to demonstrate a unique therapeutic strategy for TBI focusing on the activation of leukocytes, especially neutrophils that cause the release of nuclear and granular contents to form an extensive web-like structure of DNA called neutrophil extracellular traps (NET). In TBI, the mechanism of injury-induced formation of NET and its mechanistic regulatory role in thrombosis have remained elusive. Moreover, it is unclear whether blocking NET formation provides better outcomes after TBI. Therefore, Dr. Muneer’s novel research efforts to suppress the formation of NET will provide critical information potentially supporting a valuable new therapeutic strategy to enhance functional recovery following TBI.

“My research team and I will study an approach to suppressing the formation of NET, which may be a valuable therapeutic strategy, and analyze the efficacy of the therapy in the functional recovery level after TBI,” said Dr. Muneer.

“The Neuroscience Institute at JFK University Medical Center has been in existence for over 30 years,” said Gay Holstein, PhD, translation research, Neuroscience Institute at JFK University Medical Center. “We are honored to receive this research grant and look forward to the findings.”

Ihor Sawczuk, M.D.

“TBI is such an omnipresent problem, it’s critical to have our talented researchers findings new ways to improve and lengthen lives for this significant patient population,” said Ihor Sawczuk, M.D., FACS, president of Academics, Research, and Innovation at Hackensack Meridian Health, founding chair of the Hackensack Meridian Health Research Institute, and associate dean of Clinical Integration and professor and chair emeritus of Urology at the Hackensack Meridian School of Medicine.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

- Advertisement -

spot_img

- Advertisement -

Northwell Cardiothoracic Programs Have Nation’s Highest Success Rates

5 Northwell Cardiothoracic Programs (Northwell) include: Long Island Jewish Hospital, Lenox Hill Hospital, South Shore University Hospital, Staten Island University Hospital and the Sandra Atlas Bass Heart Hospital at North Shore University Hospital – received three-star ratings in their respective fields – the highest quality rating possible.

COTA, Baptist Health South Florida, and PreciseDx Announce Collaboration on the AI-Enabled Breast Cancer Recurrence Risk Assessment, PreciseBreast™

“AI has the potential to augment human learning and improve the accuracy and precision of cancer diagnostics and treatments,” said Dr. C.K. Wang, chief medical officer, COTA. “It is critical that we evaluate these tools against the current standard of care to validate their efficacy and build trust in AI and new technologies.”

AscellaHealth CEO, Dea Belazi, Honored as a 2024 PM360 Elite 100 Winner

Dea Belazi said, "This honor truly belongs to the entire AscellaHealth team in recognition of their expertise, dedication and ongoing work that enables patients with complex, chronic conditions to access specialty pharmaceuticals and novel therapies that enhance clinical outcomes."

By using this website you agree to accept Medical Device News Magazine Privacy Policy